全文获取类型
收费全文 | 8615篇 |
免费 | 609篇 |
国内免费 | 89篇 |
专业分类
耳鼻咽喉 | 105篇 |
儿科学 | 296篇 |
妇产科学 | 292篇 |
基础医学 | 932篇 |
口腔科学 | 160篇 |
临床医学 | 931篇 |
内科学 | 1862篇 |
皮肤病学 | 215篇 |
神经病学 | 865篇 |
特种医学 | 228篇 |
外科学 | 1405篇 |
综合类 | 166篇 |
一般理论 | 3篇 |
预防医学 | 421篇 |
眼科学 | 140篇 |
药学 | 645篇 |
中国医学 | 70篇 |
肿瘤学 | 577篇 |
出版年
2023年 | 43篇 |
2022年 | 101篇 |
2021年 | 219篇 |
2020年 | 106篇 |
2019年 | 197篇 |
2018年 | 236篇 |
2017年 | 166篇 |
2016年 | 186篇 |
2015年 | 253篇 |
2014年 | 313篇 |
2013年 | 434篇 |
2012年 | 564篇 |
2011年 | 624篇 |
2010年 | 378篇 |
2009年 | 355篇 |
2008年 | 519篇 |
2007年 | 508篇 |
2006年 | 520篇 |
2005年 | 461篇 |
2004年 | 448篇 |
2003年 | 326篇 |
2002年 | 309篇 |
2001年 | 275篇 |
2000年 | 216篇 |
1999年 | 217篇 |
1998年 | 59篇 |
1997年 | 60篇 |
1996年 | 54篇 |
1995年 | 33篇 |
1994年 | 45篇 |
1993年 | 44篇 |
1992年 | 100篇 |
1991年 | 102篇 |
1990年 | 104篇 |
1989年 | 97篇 |
1988年 | 80篇 |
1987年 | 71篇 |
1986年 | 58篇 |
1985年 | 56篇 |
1984年 | 54篇 |
1983年 | 37篇 |
1982年 | 16篇 |
1981年 | 25篇 |
1980年 | 20篇 |
1979年 | 40篇 |
1978年 | 23篇 |
1977年 | 20篇 |
1976年 | 23篇 |
1975年 | 19篇 |
1974年 | 23篇 |
排序方式: 共有9313条查询结果,搜索用时 15 毫秒
121.
Teh-Ying Chou Chao-Hua Chiu Ling-Hui Li Chun-Yen Hsiao Chin-Yuan Tzen Kuo-Ting Chang Yuh-Min Chen Reury-Perng Perng Shih-Feng Tsai Chun-Ming Tsai 《Clinical cancer research》2005,11(10):3750-3757
PURPOSE: Mutations in epidermal growth factor receptor (EGFR) can be used to predict the tumor response of patients receiving gefitinib for non-small cell lung cancer (NSCLC). We investigated the association between mutations in EGFR tyrosine kinase domain and tumor response and survival in gefitinib-treated NSCLC patients. EXPERIMENTAL DESIGN: EGFR mutations in exons 18 to 21 were analyzed by DNA sequencing of paraffin-embedded tumor tissues from gefitinib-treated NSCLC patients. The results were correlated with clinical variables. RESULTS: EGFR mutations were found in 61.1% (33 of 54) of cases; response rate and disease control rate were 56.8% and 68.5%, respectively. There was no significant difference in mutation rates between adenocarcinoma (29 of 43) and nonadenocarcinoma (4 of 11; P = 0.085). However, all four nonadenocarcinomas with EGFR mutations had no response to gefitinib. Presence of EGFR mutations was the only independent predictor for disease control (P = 0.003) and tumor response (P = 0.017) in multivariate analysis; positive predictive values were 87.9% and 70.8% and negative predictive values were 61.9% and 69.2%, respectively. In comparison with patients whose tumor was negative for EGFR mutations, patients with EGFR mutations had better progression-free survival (median, 7.6 versus 1.7 months; P = 0.011) and overall survival (median, 14.7 versus 4.7 months; P = 0.046). CONCLUSIONS: Mutations in EGFR tyrosine kinase correlate with treatment response and survival in gefitinib-treated NSCLC patients and can be used as a predictive and prognostic factor. Thus, analysis of EGFR tyrosine kinase mutations in lung adenocarcinoma is of clinical significance, as it can permit the customization of treatment with EGFR tyrosine kinase inhibitors. 相似文献
122.
123.
124.
125.
126.
127.
128.
ABSTRACT: BACKGROUND: AMP-activated protein kinase (AMPK) has recently been considered as a potential target for cancer therapy. However, the expression status of various subunits of the heterotrimeric AMPK in human cancers is rarely reported. We decided to determine their expressions in ovarian carcinomas and their relationships with the disease. METHODS: Expressions and locations of the AMPK-alpha1, -alpha2, -beta1, -beta2, -gamma1 and -gamma2 were detected by quantitative PCR (Q-PCR) and immunohistochemical staining (IHC). Their expression levels in ovarian tumors were compared with normal controls and also correlated with clinicopathological parameters. RESULTS: Except AMPK-alpha1, expressions of the other five AMPK subunits are significantly higher in ovarian carcinomas as determined by Q-PCR. Although IHC detection of AMPK-gamma1 and -gamma2 were not successful, over-expressions of AMPK-alpha2, -beta1, and -beta2 were further confirmed by IHC. Over-expressions of various AMPK subunits occurred independently and were mainly detected in the cytoplasm. Interestingly, AMPK-alpha2 and -beta1 were also detected in the nucleus and cell membrane, respectively. Clinical correlation analyses indicate that expressions of different AMPK subunits are associated with different subtypes of carcinoma. High expression of AMPK-alpha2 is significantly associated with endometrioid carcinomas. On the other hand, high expressions of AMPK-beta and -gamma subunits are associated with mucinous and serous carcinomas, respectively. Furthermore, high expressions of AMPK-beta1 and -gamma2 are also associated with early and late stages of disease, respectively. Finally, patients with high expression of AMPK-alpha2 had better prognosis. CONCLUSIONS: Aberrant expressions of AMPK subunits may play important roles in ovarian carcinogenesis. Each AMPK subunit may have its own function other than just a component of the AMPK molecule. Correlations with clinical parameters suggest that expressions of AMPK subunits have different clinical implications in ovarian cancer development. 相似文献
129.
130.